Insider buying last 90 days
No open-market insider purchases were filed for OPK in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every OPK insider filing, plotted on the chart in Gekko.Open OPK in Gekko
NASDAQ: OPK
Opko Health (OPK) Stock Analysis & Forecast
Oct 12 close
$1.380.00 (0.0%)
Gekko Brief
AI summaryOct 12 closeThis week's news centers on Opko Health's upcoming Q3 2026 earnings, projected for release after market close on 4 November 2026, with analysts anticipating a loss of $0.07 per share on revenues of $136.62 million; an earnings conference call is scheduled for 28 October 2026. A separate comparison piece weighed Opko Health against Ardent Health (ARDT) across profitability, valuation, and other metrics.
OPK closed at $1.38, sitting between its 50-day average of $1.51 and 200-day average of $1.32, reflecting a mixed trend. The GekkoIndex reads 66.8, placing the stock in the Accumulation zone. Shares trade 36.4% below Gekko Fair Value of $2.17. Over the past month the stock moved -12.1%, while the three-month and six-month returns stand at 13.1% and 17.9% respectively; the one-year return is -11.5%. The 52-week range spans $0.98 to $1.75.
Looking ahead, earnings are due on 4 November 2026, 23 days away, falling inside a typical 20-trading-day holding window. Historical seasonality from this point in the calendar shows the next 20 trading days averaging -2.3% across 5 years, with gains occurring in 2 of those years. Analyst coverage includes 3 firms, with 2 rating the stock a buy and 1 a hold, and a consensus price target of $4.38, representing 217% upside from current levels.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Opko Health price vs fair value
Close $1.38200-day averageGekko Fair Value $2.17
Opko Health quick facts
- Market cap
- $1.03B
- P/E ratio
- —
- Forward P/E
- 53.8
- EPS, TTM
- −$0.09
- Revenue, TTM
- $587.9M
- Profit margin
- -12.4%
- Dividend yield
- —
- Beta
- 1.50
- Volume
- 1.01M avg 2.12M
- 1-year return
- −11.5%
- Typical daily move
- ±4%
- Typical 20-day move
- ±8.9%
- 50-day average
- $1.51
- 200-day average
- $1.32
- Next earnings
- Nov 4 after close
- Shares outstanding
- 746.3M
Opko Health swing-trade checklist
Opko Health scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendmixed
Averages disagree
Close $1.38 sits between the 50-day ($1.51) and 200-day ($1.32) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
66.8, Accumulation
Reading 66.8 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
36.4% below
Price is 36.4% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−2.3% on average
From this point in the calendar, the next 20 trading days averaged −2.3% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Opko Health stock chart and price history
Opko Health closed at $1.38 on Oct 12, 2026, −11.5% over the past year, inside a 52-week range of $0.98 to $1.75.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −12.1%
- 3 months
- +13.1%
- 6 months
- +17.9%
- 1 year
- −11.5%
The full OPK chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open OPK in Gekko
Follow Opko Health through every session
Put OPK on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track OPK in GekkoFree for 7 days. No credit card required.
About Opko Health
Opko Health works across two broad fields in healthcare: laboratory diagnostics and pharmaceutical products. Its diagnostics arm, BioReference Laboratories, runs a wide range of testing services used to detect, diagnose, and track disease, including specialized areas like molecular diagnostics, genetics, anatomical pathology, and women's health. This side of the business also includes a point-of-care blood testing instrument and the 4Kscore test used in prostate cancer evaluation. On the pharmaceutical side, the company is best known for Rayaldee, a treatment for secondary hyperparathyroidism in patients with chronic kidney disease.
Opko's customers in diagnostics include medical practices, clinics, hospitals, employers, and government bodies. Its pharmaceutical operations extend beyond Rayaldee into a pipeline of experimental treatments, such as compounds aimed at type 2 diabetes, obesity, and a long-acting growth hormone developed with Pfizer. The company also makes and distributes active pharmaceutical ingredients, generics, nutraceuticals, veterinary and eye-care products, food supplements, and over-the-counter items, along with medicines for conditions like cardiovascular disease, infections, and digestive disorders.
Opko Health has operations spanning the United States, Ireland, Chile, Spain, Israel, and Mexico, among other markets. Its shares are listed on the NASDAQ under the ticker OPK.
- Listed
- NASDAQ
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- opko.com
Opko Health GekkoIndex: the smart money zone
Opko Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 66.8, in the Accumulation zone, up 7.8 points over five sessions.
66.8Accumulation
Up 7.8 points over five sessions, from the Neutral zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 28 | +4.8% | +11.4% | ||
| Accumulation (current zone) | 219 | +0.4% | +5.5% | ||
| Neutral | 393 | +0.3% | −0.4% | ||
| Distribution | 37 | −0.3% | −0.5% | ||
| Selling | 5 | Too few readings yet | |||
Average OPK share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the OPK price, zone by zone.Track OPK in Gekko
Is Opko Health stock overvalued? Gekko Fair Value
Opko Health trades 36.4% below Gekko Fair Value of $2.17, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Opko Health shares are worth, recalculated every trading day.
$2.17
Gekko Fair Value, Oct 10, 2026
36.4% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open OPK in Gekko
Opko Health insider and Congress trading
No open-market insider purchases were filed for Opko Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in OPK were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for OPK, plotted on the chart in Gekko.Open OPK in Gekko
Buybacks
Opko Health has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $13.02M
- As a share of market cap
- 1.26%
- Trailing four quarters
- $46.57M
From company filings.
Opko Health earnings: next date and track record
Opko Health reports on Nov 4, 2026, after the close (23 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 23 days away
- EPS estimate
- −$0.07
- Revenue estimate
- $136.6M
5 of 8reports beat the EPS estimate
±8.6%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 27, 2026 AI summary
- What they said
- OPKO Health reported Q2 2026 results with improved operating efficiency and a strong cash position. ModeX has five clinical programs in oncology, immunology, and vaccines, with a sixth in-vivo CAR-T asset expected to begin trials by end of 2026 or early 2027. Key pipeline assets include MDX2001 (solid tumors), MDX2003 (B-cell cancers), and a GLP-1 glucagon candidate initiating Phase I/IIa. NGENLA, partnered with Pfizer, continues gaining market share.
- Guidance
- MDX2001 dose escalation expected to conclude by Q3/early Q4 2026, with early data at a medical conference in late 2026 or early 2027. Merck-funded EBV vaccine Phase II design expected by year-end, with potential Phase II progression in 2027. MDX2004 preliminary data anticipated in 2027.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 27, 2026 | −$0.01 est −$0.08 | $163.5M est $131.2M | +35.2% |
| Apr 28, 2026 | −$0.07 est −$0.07 | $124.2M est $130.5M | −7.5% |
| Feb 26, 2026 | −$0.04 est −$0.07 | $148.5M est $139.8M | +1.7% |
| Oct 29, 2025 | $0.03 est −$0.02 | $151.7M est $139.8M | +1.4% |
| Jul 31, 2025 | −$0.19 est −$0.12 | $156.8M est $165.7M | −11.2% |
| Apr 30, 2025 | −$0.10 est −$0.06 | $150.0M est $165.7M | −3.6% |
| Feb 27, 2025 | $0.01 est −$0.08 | $183.6M est $155.4M | +4.8% |
| Nov 7, 2024 | −$0.03 est −$0.09 | $173.6M est $155.4M | +3.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Opko Health stock forecast and analyst price targets
Analysts’ average 12-month price target for Opko Health is $4.38, +217.0% from the last close, from 3 firms rating the stock in the last 90 days.
$4.38consensus 12-month target, +217.0% from the last close
Each firm’s latest rating in the last 90 days: 3 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 14 | H.C. Wainwright | $3 | +117.4% |
| Jul 28 | H.C. Wainwright | $3 | +117.4% |
| Jul 28 | Barrington | — | — |
| Jul 28 | Piper Sandler | $3 | +117.4% |
+5.5%average 20-day move after past Accumulation readings
−2.3%average move over the next 20 trading days in the last 5 years
±4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Opko Health seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Opko Health averaged −2.3% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.4% | 2 of 5 |
| Next 10 trading days | −3.9% | 0 of 5 |
| Next 15 trading days | −3.5% | 3 of 5 |
| Next 20 trading days | −2.3% | 2 of 5 |
| Next 30 trading days | −0.9% | 3 of 5 |
For scale, OPK’s typical 20-trading-day move in either direction is about 8.9%.
Opko Health market cap and key statistics
Opko Health’s market cap is $1.03B and revenue of $587.9M over the last twelve months.
Valuation
- Market cap
- $1.03B
- Forward P/E
- 53.8
- EPS, TTM
- −$0.09
- Gekko Fair Value
- $2.17
Trading
- Volume
- 1.01M
- Avg volume, 20 days
- 2.12M
- 52-week high
- $1.75
- 52-week low
- $0.98
- Shares outstanding
- 746.3M
Financials
- Revenue, TTM
- $587.9M
- Profit margin
- -12.4%
- Return on equity
- -5.9%
- Quarterly earnings growth, YoY
- −12.6%
Risk and income
- Beta
- 1.50
- Typical daily move
- ±4%
- Typical 20-day move
- ±8.9%
Opko Health stock news this week
2 headlines about Opko Health from the past week, newest first, each linking to the publisher.
- OPKO Health Q3 2026 Earnings Date and EstimatesMarketBeat, Oct 9
- Comparing Ardent Health (NYSE:ARDT) & OPKO Health (NASDAQ:OPK)Defense World, Oct 7
Opko Health peers
Opko Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 2.5% below |
| GHGuardant Health | Accumulation | 10.0% below |
| SOLVSolventum | Accumulation | 20.5% below |
| BTSGBrightSpring Health Services | Neutral | 2.8% above |
| EHCEncompass Health | Neutral | 7.3% above |
| DVADaVita | Neutral | 14.6% below |
A peer links to its own page where one exists.
Opko Health stock FAQ
What is Opko Health’s market cap?
Opko Health’s market cap is $1.03B at the Oct 12, 2026 close of $1.38, with 746.3M shares outstanding.
What is the Opko Health stock forecast?
The consensus analyst 12-month price target for Opko Health is $4.38, +217.0% from the last close. Of the 3 firms that rated the stock in the last 90 days, 2 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Opko Health stock overvalued or undervalued?
On Gekko’s estimate Opko Health is undervalued: the Oct 12, 2026 close of $1.38 is 36.4% below Gekko Fair Value of $2.17. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Opko Health report earnings next?
Opko Health is expected to report on Nov 4, 2026, after the market closes (23 days away). Analysts expect earnings of −$0.07 per share on revenue of $136.6M. Opko Health beat the earnings estimate in 5 of its last 8 reports, moving 8.6% on average across the report.
What is Opko Health’s 52-week high and low?
Opko Health’s 52-week high is $1.75 and its 52-week low is $0.98; it closed at $1.38 on Oct 12, 2026, −11.5% over the past year. Over the last five years the shares peaked at $5.25 on Dec 28, 2021.
Is Opko Health stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 1 as mixed (trend) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Opko Health the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.